Market open

Novavax/NVAX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Novavax

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

Ticker

NVAX
Trading on

Industry

Biotechnology

Employees

1,543

Novavax Metrics

BasicAdvanced
$2B
Market cap
-
P/E ratio
-$2.28
EPS
1.97
Beta
-
Dividend rate
$2B
1.97
$23.86
$3.53
6.5M
1.039
0.934
-58.862
-61.045
-18.79%
-10.21%
49.63%
1.648
-4.67
-3.64
-69.059
-38.17%
-67.56%
-5.81%
-45.15%

What the Analysts think about Novavax

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Novavax stock.

Novavax Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Novavax Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy NVAX

$

Sign up or log in to buy
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Novavax stock?

Novavax (NVAX) has a market cap of $2B as of October 15, 2024.

What is the P/E ratio for Novavax stock?

The price to earnings (P/E) ratio for Novavax (NVAX) stock is 0 as of October 15, 2024.

Does Novavax stock pay dividends?

No, Novavax (NVAX) stock does not pay dividends to its shareholders as of October 15, 2024.

When is the next Novavax dividend payment date?

Novavax (NVAX) stock does not pay dividends to its shareholders.

What is the beta indicator for Novavax?

Novavax (NVAX) has a beta rating of 1.97. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.